Gyungah R. Jun
Co-leader, Project 3, FHS-BAP
Dr. Jun is a genetic epidemiologist who focuses on genome guided drug discovery for Alzheimer’s disease (AD). She is a Steering Committee member at the Framingham Heart Study Brain Aging Program (FHS-BAP) and Co-Leader for the Project 3, entitled as “Role of classical complement pathway underling glial phenotypes and multiple pathologies in Alzheimer’s disease and cerebrovascular disease”. She is leading genetic and molecular profiling in blood and brain in FHS to identify genetic evidence and plasma biomarkers targeting classical complement pathway in AD therapeutics. Dr. Jun is involved with the Alzheimer’s Disease Genetics Consortium and the International Genomics of Alzheimer’s Project to identify AD risk genes within APOE genotype subgroups and across multi-ethnic populations. Previously, Dr. Jun was the Director of Neurogenetics and Integrated Genomics for the Andover Innovative Medicines (AiM) Institute, Eisai Inc. involved in genome-guided drug discovery projects for AD. In 2018, she rejoined the BU School of Medicine as a full-time professor and contributed to establish large, collaborated research programs. Dr. Jun is a founding member and one of four PIs for the Asian Cohort for Alzheimer’s Disease (ACAD) Consortium and chairs the Data Management and Data Analysis work groups. She is a Director at the Genome Guided Drug Discovery (GGDD) Core at the AI4AD consortium, which is a large coordinated national initiative for AD therapeutics working on transformative Artificial Intelligence approaches using high throughput human big data.